Postagem em destaque

CRISPR crunch

Genetic engineering CRISPR crunch A row over who invented a new gene-editing technique heats up Feb 20th 2016  |  WASHINGTON, DC  |...

terça-feira, 24 de novembro de 2015

Redação do pedido de Patente: a chave para o sucesso

Escrevo hoje sobre um tema muito relevante aqui no Brasil: redação de pedidos de patentes.

Em meu trabalho de especialização, descrevo os principais erros cometidos na hora de escrever um pedido de patentes. Esses erros, por sua vez, podem culminar no indeferimento do pedido.

Lembrando que a AN127 foi revogada. Contamos hoje com a Resolução Normativa 30 e 31 de 2013 para os pedidos de patentes!

Nesse sentindo, encontrei uma reportagem muito relevante sobre o tema e queria compartilhar com vocês.

Por Lilian Burgardt
Escrever bem não é uma tarefa fácil, especialmente quando o tema exige o uso da linguagem formal e, ao mesmo tempo, um texto claro, conciso e objetivo, como é o caso de um pedido de Patente. Sendo assim, para muitos pesquisadores, especialmente para os que se especializam em áreas técnicas, pôr sua invenção no papel se transforma em um verdadeiro sofrimento. No entanto, há como driblar estas dificuldades e se sair bem na redação de um pedido de Patente - desde que o requerente se disponha a dedicar boa parte de seu tempo à leitura.
Durante o curso sobre Redação de Pedido de Patentes, ministrado pela analista de Patentes do INPI (Instituto Nacional de Propriedade Industrial), Elisabeth Omar Ribeiro Rosa, no último dia 07 de julho, em Campinas, a surpresa. Entre os quase 90 participantes presentes, entre alunos e pesquisadores, apenas três afirmaram já ter lido algum pedido de Patente. "Esse é um comportamento que o pesquisador brasileiro precisa mudar. Para se escrever bem é fundamental apostar na leitura e releitura de textos", declara.
Neste caso, quem nunca abriu um pedido de Patente em sua área para ter ao menos uma base de como iniciar sua redação já está em desvantagem. No entanto, a analista destaca que não basta sair por aí fazendo buscas e análises sem critério, ou tentar ganhar tempo lendo apenas título e resumo dos pedidos. O pesquisador interessado deve ir à fundo, procurar em outras redações linhas de pensamento e informações que vão ao encontro do seu trabalho para que, além de servir de exemplo, os textos também possam servir como fundamentação teórica de seu pedido. "Tendo isso em mente, o pesquisador já terá avançado no processo de aprendizagem da redação de um bom pedido de Patente", revela.
Além de buscar material para fundamentar seu trabalho, o pesquisador deve seguir alguns passos para obter um bom resultado em sua redação. O primeiro deles é ter como livro de cabeceira o Ato Normativo 127, descritivo das regras para escrever um pedido de Patente dentro dos padrões legais. "A maioria dos pesquisadores não leu ou não compreendeu as questões presentes no Ato Normativo 127, o que é uma grande falha, já que ele serve como tutorial para quem vai fazer este tipo de redação", lamenta.(Clique aqui e acesse o Ato Normativo 127).
Para Elisabeth, o Ato Normativo é de extrema importância pois tem as especificações corretas para que o pesquisador consiga identificar em qual categoria se encaixa seu projeto, seja ela PI (Patente de Invenção), que corresponde a uma invenção tecnológica em que consta o desenvolvimento de um novo processo, ou Patente MU (Modelo de Utilidade), que corrresponde a uma modificação de um objeto que tenha por objetivo sua melhor utilização. Fator crucial a ser observado pelo pesquisador antes de depositar sua Patente.
Isso porque, cada categoria possui exigências distintas, descritas a seguir, que, se desrespeitadas, são responsáveis pela reprovação do pedido. "Por exemplo, um pesquisador que tem uma invenção PI e deposita como MU não conseguirá mudar de categoria após o depósito da Patente pois os padrões de descrição do Modelo de Utilidade são completamente diferentes do pedido de Patente de Invenção, que são, geralmente, mais complexos justamente pela importância da invenção", explica. "Nestes casos, infelizmente, o pedido será indeferido por insuficiência descritiva", lamenta.
Segundo Elisabeth, uma vez que o pedido de Patente é publicado, outro pesquisador pode efetuar o descritivo correto e apresentá-lo ao INPI. Além disso ela revela que, 95% das Patentes de Polímeros, na área química, por exemplo, são concedidas à empresas multinacionais, que, assim como na maior parte das áreas de Patente, está muito à frente do Brasil. "? muito triste indeferir a pequena porcentagem de pedidos de pesquisadores brasileiros, especialmente por falta de suficiência descritiva. Por isso, é fundamental que a redação esteja impecável e que o pesquisador saiba identificar quando sua invenção corresponde a categoria de PI ou de MU", declara.
Identificando PI e MU
Para a pesquisadora, embora em alguns casos as diferenças pareçam sutis, as características das invenções são bem diferentes. "Costumo dizer que PI tem como base a criação de uma solução, uma técnica ou um sistema que traga um novo resultado. Já a patente MU está intrínsecamente relacionada à forma, ao design", diz.
Quando se trata da invenção de um processo, ou seja, de PI, as regras costumam ser bastante rígidas. O pesquisador deve descrever sua invenção apresentando o estado da técnica atual, citando documentos que comprovem os problemas técnicos existentes, e, a partir daí, comprovar as vantagens que sua invenção pode trazer em benefício ao setor de maneira que um técnico no assunto possa compreendê-la. Ou seja, é preciso buscar referências na concorrência comprovando que sua técnica pode superar o produto, apontando as falhas e as vantagens da sua invenção. "Não basta falar que a técnica de desenvolvimento de seu pneu, por exemplo, oferece maior segurança e resistência em relação aos que os estão disponíveis no mercado. ? preciso comprovar", diz.
Neste caso, o pesquisador deve apontar os tipos de processos de produção de pneus existentes e suas falhas comparando-os com sua invenção. Assim, será possível ter uma panorama do setor e conceder a Patente. Estas informações devem estar muito bem detalhadas no Relatório Descritivo do pedido de Patente, segundo a analista, a etapa mais importante da redação. "? no Relatório Descritivo que o pesquisador deve detalhar sua invenção, nele é que irão constar informações precisas sobre o projeto, vantangens e desvatangens em relação à concorrência. Portanto, esta é a etapa que deve exigir maior nível de detalhamento e atenção do pesquisador", revela.
Por se tratar da parte mais importante do pedido de Patente, Elisabeth declara que é neste campo em que se deve buscar as informações da concorrência. "Se existirem 200 indústrias de fabricação de pneus, o pesquisador deve ler um por um dos Relatórios Descritivos dos pedidos de Patente para certificar-se de que sua invenção não está em conflito com o trabalho desenvolvido por outro pesquisador ou indústria", diz.
Vale ressaltar novamente: nada de ler apenas título e resumo. Se o pesquisador quer atestar que sua invenção realmente supre as falhas e necessidades do setor à que pertence, por mais que a concorrência seja grande, é fundamental buscar fundamentação teórica. "Se o trabalho estiver sendo desenvolvido por uma grande empresa, cuidado redobrado. O pedido tem que ser forte, não pode oferecer riscos à companhia, afinal de contas, o registro de Patente está lidando, acima de tudo, com dinheiro e é traduzido em um grande investimento", reforça.
Embora a Patente de MU não exija grande nível de detalhamento, já que se trata de uma melhoria na utilização de um objeto, também possui necessidades específicas que devem ser observadas. Dentro do Relatório Descritivo, que nesta categoria também desempenha papel fundamental, cabe ao pesquisador apontar as falhas da concorrência (sem a necessidade de uma busca detalhada de seus processos), apontando as soluções que sua invenção pode trazer.
Um exemplo disso é a criação do lápis sextavado, explica a analista. "O pesquisador pode relatar que decidiu criar este lápis pois o lápis cilíndrico, em superfícies lisas, e/ou inclinadas, pode deslizar e cair, quebrando o grafite, enquanto o seu, devido ao design, resulta em uma fixação", diz. Outro exemplo que pode ser utilizado é o caso do apagador de quadro. "O simples apagador, de superfície lisa, muitas vezes deslizava das mãos dos professores. Após a adpatação de pequenas ranhuras, tornou-se mais estável e fácil de segurar", diz.
Agora que você já observou as principais diferenças entre os pedidos de PI (Patente de Invenção) eMU (Modelo de Utilidade), clique sobre cada um dos links para verificar, passo a passo, os itens que devem ser observados para a redação de um pedido de Patente.
Se mesmo assim, você pesquisador, ligado à universidade, ainda tiver dúvidas e dificuldades quanto à redação do pedido de Patente informe-se sobre a existência de uma agência de pedido de Patente em sua instituição. A Universidade Estadual de Campinas e a Universidade Federal de Minas Gerais, por exemplo, oferecem este serviço para seus pesquisadores. Caso sua universidade não disponha deste recurso, outra opção interessante pode ser pedir auxílio ou Consultoria do INPI, que, segundo Elisabeth, dispõe de uma equipe de analistas para tirar dúvidas e conduzir o pesquisador ao caminho certo para redigir uma proposta de sucesso. 
Para obter orientação do INPI na preparação do pedido de patente, o pesquisador deverá dirigir-se à sede do Instituto, ou entrar em contato pelos telefones: (21) 2139-3314 ou (21) 2139-3797. Para informações sobre o processamento administrativo, pedido de patente (petições, anuidades, etc.) o caminho é via SEAPAT (Seção de Apoio Técnico) ou então pelo telefone (21) 2139-3350. Para outras informações, esclarecimentos e informações sobre pedidos de patente é possível contatar a Diretoria de Patentes pelo telefone: (21) 2139-3592 ou através do e-mail: patente@inpi.gov.br.

Leia mais em:

sábado, 21 de novembro de 2015

Innovation: French

France: a leader in startups and innovative companies

- France is ranked second in Europe and fourth worldwide for the most number of patents filed.
- According to a 2013 Thomson Reuters report, 12 French groups (including AIRBUS, L’OREAL, SAINT GOBAIN, ALCATEL LUCENT and VALEO) are among the top 100 global innovators, making France the third top country, after the U.S. and Japan.
- In Deloitte’s 2013 list of the 500 fastest growing startups in Europe, Africa and the Middle East, French companies dominate for the fourth year in a row. Eighty-six French companies made the list, including Ymagisin the top spot.In 2012, Criteo, now quoted on NASDAQ, ranked first.
- President Hollande recently announced a streamlined "one-stop shop process" to attract foreign startups in France, combined with a financial contribution to help them launch.
- Young Entrepreneurs Initiative (YEI) is the French-American accelerator for innovative American startups looking to explore opportunities in France.

France’s commitment to innovation

- France has the largest research and development (RD) tax credit in Europe,which covers 30 percent of all RD costs up to $140 million, and 5 percent above this threshold. Innovation expenses incurred by small and medium-sized enterprises (SMEs) are also eligible for the research tax credit (up to $110,000 per year). This tax benefit for innovative companies totals$69 billion.
- France has a $65 billion National Investment Program aimed at increasing growth potential by fostering investment in higher education and training, scientific and technological research, world-class industrial sectors and innovative SMEs, green technologies and the digital economy. $300 million is specifically earmarked to stimulate the creation and development of French digital companies in France and abroad.
- In France, there are 71 innovation clusters, inspired by the American model, that bring together universities, private companies and research centers, as well as new technology research institutions benefiting from public/private joint investments. These clusters are attracting international partnerships, and 17 cooperation projects with American partners are already in place.
- "Innovation 2030", a worldwide innovation challenge, was launched in December 2013. The challenge is open to French and foreign startups, as well as innovative companies, and is supported by $400 million from the French public investment bank. The goal is to co-finance innovative projects in seven strategic fields: energy storage, recycling of metals, development of marine resources, plant proteins and plant chemistry, personalized medicine, the "silver economy" (innovation in the service of senior citizens) and big data.

Read more:

terça-feira, 10 de novembro de 2015

What do you think about it? Do patents really promove innovation and acess? A question of utility

Intellectual property

A question of utility

Patents are protected by governments because they are held to promote innovation. But there is plenty of evidence that they do not


THE Great Exhibition, staged in London in 1851, was intended to show off the inventive genius of Victorian Britain. In doing so it sparked a hardfought debate on intellectual property. On one side were public figures horrified at the thought of inviting the whole world to see the nation’s best ideas, only to have most of it go straight home and copy them. They called for the patent system to be made cheaper and easier to navigate, and for the rights it conferred to be more forcefully upheld. These demands, though, were met with a backlash. Supported by economic liberals who had successfully fought for the repeal of the protectionist Corn Laws a few years earlier, this side of the debate argued that free trade and competition were good for the economy; that patents were a restraint on both; and that therefore patents should be not reformed, but done away with.
The Economist, founded by opponents of the Corn Laws, was an enthusiastic promoter of this abolitionist movement. A leader in our July 26th issue that year thundered that the granting of patents “excites fraud, stimulates men to run after schemes that may enable them to levy a tax on the public, begets disputes and quarrels betwixt inventors, provokes endless lawsuits [and] bestows rewards on the wrong persons.” In perhaps our first reference to what are now called “patent trolls”, we fretted that “Comprehensive patents are taken out by some parties, for the purpose of stopping inventions, or appropriating the fruits of the inventions of others.”
Arguing that patents “rarely give security to really good inventions” and fail at their job of encouraging innovation by rewarding inventors for their efforts, we backed the abolitionists in a debate over patent reforms then in Parliament. Our knockout argument: most of the wonders of the modern age, from mule-spinning to railways, steamships to gas lamps, seemed to have emerged without the help of patents. If the Industrial Revolution didn’t need them, why have them at all?
From Trevithick to trolls
The debate raged on for years and through several changes of government. In 1883, though, Parliament decided that instead of killing patents, it would improve them. The struggle has been taken up again at various times and places. In the first half of the 20th century, for example, many Americans worried that patents were helping corporations such as AT&T monopolise whole industries. In 1938 the Federal Communications Commission urged Franklin Roosevelt to replace them with compulsory licensing. But whenever the issue comes up, lawmakers conclude that the patent system can be perfected and another round of reforms is all that is needed.
During all this time the conceptual and geographical domain of the patent-clerk has expanded. The ability to patent has been extended from physical devices to software and stretches of DNA, not to mention—notably in America—to business processes and financial products. The fear of international competition that came to the fore at the time of the Great Exhibition has seen the system spread around the world, typically as the price that smaller or poorer nations pay for access to the markets of the richer and more lawyered-up. It was this sort of international pressure that brought the Netherlands’ 19th-century experiment with patent abolition to an end. It has been the lure of membership of the World Trade Organisation that has pushed patent rights into emerging economies such as China’s. One of the reasons why talks on the proposed Trans-Pacific Partnership, a trade deal involving countries which produce 40% of the world’s economic output, ended inconclusively last month was the strong patent protection Western countries wanted for biotech-based drugs.
One argument backers like to make is that patents serve the public good. That was not their original purpose. As one of Britain’s 19th-century abolitionists, John Lewis Ricardo, a telegraph entrepreneur and a nephew of David Ricardo, a leading economist, noted in Parliament, sovereigns first introduced them as nice little earners; in the early 17th century King James I was raising £200,000 a year from granting patents. But over time they came to be seen as beneficial to the people as well as to the monarch—a tool with which to “promote the progress of science and useful arts”, as the American constitution puts it.
The public-good position on patents is simple enough: in return for registering and publishing your idea, which must be new, useful and non-obvious, you get a temporary monopoly—nowadays usually 20 years—on using it. This provides an incentive to innovate because it assures the innovator of some material gain if the innovation finds favour. It also provides the tools whereby others can innovate, because the publication of good ideas increases the speed of technological advance as one innovation builds upon another.
This sounds plausible. But is it true? There is much room for doubt. The evidence that the current system encourages companies to invest in research in a way that leads to innovation, increased productivity and general prosperity is surprisingly weak. A growing amount of research in recent years, including a 2004 study by America’s National Academy of Sciences, suggests that, with a few exceptions such as medicines, society as a whole might even be better off with no patents than with the mess that is today’s system.
The post-hoc patent
Michele Boldrin and David Levine, two economists, pulled all this research together in abook published in 2008 and in “The Case Against Patents”, a 2012 paper for the Federal Reserve Bank of St Louis. They argue that patents are neither as good at rewarding innovation nor as helpful in propagating it as claimed.
Take, first, the idea that patents give you a higher rate of innovation. If you look at things such as the number of inventions presented at international fairs, the evidence suggests that 19th-century countries that lacked patent systems were no less innovative than those which had them, though they did innovate in somewhat different areas. Reviewing 23 20th-century studies Mr Boldrin and Mr Levine found “weak or no evidence that strengthening patent regimes increases innovation”—all it does is lead to more patents being filed, which is not the same thing. Several of these studies found that “reforms” aimed at strengthening patent regimes, such as one undertaken in Japan in 1988, for the most part boosted neither innovation nor its supposed cause, R&D spending.
An exception to this general finding reveals another interesting point. A study of Taiwan’s 1986 reforms found that they did lead to more R&D spending in the country and more American patents being granted to Taiwanese people and enterprises. This shows that countries whose patent protection is weaker than others’ can divert investment and R&D spending to their territory by strengthening it. But it does not demonstrate that the overall amount of spending or innovation worldwide has been increased.
If patents encourage worthwhile innovation, then you might expect expansions of the patent system to bring about more of it. Studies from plant breeding suggest this is not so. In 1970 America expanded patent protection to crops that reproduce sexually; subsequent studies on wheat, which is such a crop, showed neither greater research spending nor an increase in the rate at which yields improved. Patent protection on biotech products of all kinds was expanded in the 1980s; as with the change made in 1970, the productivity of American agriculture rose at more or less the same rate after the expansion as before.
When changes in the rate of innovation do occur, they seem to have little to do with patents. Mr Boldrin and Mr Levine observe that in industries from chemicals to carmaking to computer software, waves of innovation began with a surge in inventiveness with lots of participants. Patents only started to be filed years later, once the innovation had died down and the incumbents in the maturing industry were seeking to exclude new entrants, as well as to protect themselves from their rivals’ lawsuits. Patents were a result of successful innovation; its cause was competition.
This is not to say that patents offer no genuine benefits, especially to parties with little access to capital but some ideas. But in many mature, complex manufacturing businesses—aerospace and carmaking, for example—control of the underlying intellectual property is only a small part of what is needed to create and market a world-beating, innovative product. If that were not the case, China’s makers of cars and planes, which have been given a free hand—a helping hand, some competitors say—by their government to pinch Western technology, would be vying with rich-country rivals such as BMW and Boeing. They are not.
In one of the world’s most important businesses, software, there has been something of a backlash against close-held intellectual property. Proprietary software normally does not allow the user access to the source code it depends on; open-source software gives them access to everything as long as any modification they make is made similarly accessible. This can work on a large scale—witness Android, the world’s most successful smartphone operating system.
Pitfalls and piracy
Leaving aside the spurring of innovation, what of the route patents are supposed to provide for its diffusion? That, too, is hard to spot. Mr Boldrin and Mr Levine argue that patent filings tend to be carefully written so as to obscure how the patented idea works even from experts in the field. In his history of intellectual property, “Piracy”, Adrian Johns of the University of Chicago notes that such shenanigans were already under way in the 18th century, with inventors taking care to leave out as much detail as possible from their applications. A counterpart to this defensive ploy is the filing of “submarine” patents: vague and speculative applications made by parties who then try, through various ploys, to keep the application from being granted until other people seem to be making progress on the technology in question. At that point the submarine surfaces with a view to demanding licensing fees.
If patents do not hold many advantages, why do they persist and indeed multiply? In some industries and countries they have become a measure of progress in their own right—a proxy for innovation, rather than a spur. Chinese researchers, under orders to be more inventive, have filed a flurry of patents in recent years (see chart 1). But almost all are being filed only with China’s patent office. If they had real commercial potential, surely they would also have been registered elsewhere, too.
Another reason people might file patents that they don’t need—thus explaining why anything between 40% and 90% of all patents issued are never used or licensed by their owners—is self-defence. In much of the technology industry companies file large numbers of patents (see chart 2), but this is mostly to deter their rivals: if you sue me for infringing one of your thousands of patents, I’ll use one of my stash of patents to sue you back. Such stand-offs make life hard for newcomers: a 2001 study found that fledgling microchip makers were having to spend up to $200m licensing intellectual property that might not be much use to them just to fend off lawsuits. This sort of situation might be good for the incumbents, if not for competition and the public interest; but there is a fair chance it is not good even for them. Some studies have found “thickets” of patents that make it harder for all companies to launch new products.
Even if many industries do not really need patents—and a fair few might be better off without them—there is still a strong belief that in some businesses they are vital. The example always touted is pharmaceuticals. Drugs have to undergo exceptionally expensive and long-drawn-out testing procedures to demonstrate that they are safe and effective. And once a company has laboriously demonstrated that a molecule does its job with few or manageable ill effects, its rivals could make far cheaper copies were it not for patent protection. That is why proponents of patents see it as reasonable to let Bristol-Myers Squibb have a temporary monopoly on Opdivo, its new melanoma drug, and to charge $120,000 per course of treatment in America. If the company could not do so, the argument goes, it would not have spent a fortune on getting the drug and its complex manufacturing process approved.
The Bayer necessities
However, the history of the industry raises doubts about such arguments. Until 1967 German drug companies could only patent the way they made drugs, not the formulae of the drugs themselves. Anyone could sell copies of the medicines if they found another method of making them. Yet Mr Boldrin and Mr Levine say German drugmakers produced more innovations than British ones (remember where aspirin was invented). Another interesting case is Italy, which had no patent protection for drugs until 1978. One study showed it invented a larger proportion of the world’s new medicines before that date than afterwards. Before the “reform” it had lots of copycat firms, but the biggest of these also did research on drugs of their own. They were largely wiped out once they had to pay royalties on their copycat drugs.
It is true that, encouraged by the prospects of patents, pharma companies do a lot more research today than in the 1960s and 1970s. But it is also true that they are not alone in their endeavours. Public support for biomedical research has soared over past decades; the budget of America’s National Institutes of Health is five times what it was in 1970. Mr Boldrin and Mr Levine reckon that once subsidies and tax breaks are accounted for, American private industry pays for only about a third of the country’s biomedical research. In return the patent system provides them with a great deal of income.
The drug companies claim this is a good deal; that the short-term gains a spate of cheap drugs would bring right after a putative abolition would be overshadowed by the long-term losses due to a dearth of new drugs. Looking at one industry-funded studythat reaches this conclusion, though, Mr Boldrin and Mr Levine found it quite sensitive to the discount rate applied to future benefits. In 2005 Dean Baker, an economist at the Centre for Economic and Policy Research, a think-tank in Washington, DC, took a much simpler, but still rather striking, approach: he just compared the costs imposed by the patent system with the innovation that system bought.
America’s health systems, he noted, spent $210 billion on prescription drugs that year. Based on how much cheaper generic drugs were than patented ones, Mr Baker calculated that a competitive patent-free market might have provided the same drugs for no more than $50 billion. That represented a saving of $160 billion.
The drug companies reckoned at the time that they were spending $25 billion on R&D; the government was spending $30 billion on basic medical research. The money it would have been able to save buying drugs for Medicare and Medicaid in a patent-free world have allowed the government to double that research spending, more than replacing industry’s R&D, while still leaving $130 billion in public benefit.
With America’s prescription-drug bill now $374 billion, the opportunity looks all the greater, even though the companies now say they are putting $51 billion a year into R&D. Imagining that the government could spend R&D money as effectively as the corporate sector may sound like a stretch. But a government which simply wanted to make drugs available for competitive manufacture might find various ways to get innovative results from contract research companies. Joseph Stiglitz, an economist at Columbia University, and others have suggested encouraging teams of autonomous scientists to develop new breakthrough drugs by offering those that succeed big prizes.
After a promising drug was found the final, most expensive stages of clinical trials, which measure the efficacy of a drug that has already been shown to be safe, could be publicly funded, using another portion of the huge potential savings from cheaper drugs, and conducted by independent laboratories. Once a medicine was validated, any drug company would be allowed to make it. Alternatively, the trials could be made smaller, with companies required to earn the right to manufacture a drug that had been shown to be safe by scrupulously collecting and publishing data on how the drug compared with other treatments once it was in use.
This is not as strange as it may sound. Many drug startups see their exit strategy as being bought up for a billion dollars or so by a big pharma company when their projects start to look promising. Billion-dollar prizes would provide similar incentives. Nor is it all that new: Robert MacFie, a leading Victorian patent-abolitionist, also favoured prizes.
Six bills to reform patents in some way (including in one case by overturning an earlier reform) have been proposed to the current American Congress. None seeks abolition: any lawmaker brave enough to propose doing away with them altogether, or raising similar questions about the much longer monopolies given to copyright holders, would face an onslaught from the intellectual-property lobby.
But a top-to-bottom re-examination of whether patents and other forms of intellectual-property protection actually do their job, and even whether they deserve to exist, is long overdue. Simple abolition raises problems in terms of the ethics of property rights (see leader). But reductions in the duration of exclusive rights and differentiation between those rights for different sorts of innovation are possible, and could be introduced in steps over a number of years, allowing plenty of time for any ill effects to surface. Experiments with other forms of financing innovation could be run alongside the patent system. If defenders of the patent system really seek to foster innovation, they should be prepared to do so in their own backyard.


What do you think about it? TIME TO FIX PATENTS

Innovation

Ideas fuel the economy. Today’s patent systems are a rotten way of rewarding them



IN 1970 the United States recognised the potential of crop science by broadening the scope of patents in agriculture. Patents are supposed to reward inventiveness, so that should have galvanised progress. Yet, despite providing extra protection, that change and a further broadening of the regime in the 1980s led neither to more private research into wheat nor to an increase in yields. Overall, the productivity of American agriculture continued its gentle upward climb, much as it had before.

In other industries, too, stronger patent systems seem not to lead to more innovation. That alone would be disappointing, but the evidence suggests something far worse.
Patents are supposed to spread knowledge, by obliging holders to lay out their innovation for all to see; they often fail, because patent-lawyers are masters of obfuscation. Instead, the system has created a parasitic ecology of trolls and defensive patent-holders, who aim to block innovation, or at least to stand in its way unless they can grab a share of the spoils. An early study found that newcomers to the semiconductor business had to buy licences from incumbents for as much as $200m. Patents should spur bursts of innovation; instead, they are used to lock in incumbents’ advantages.
The patent system is expensive. A decade-old study reckons that in 2005, without the temporary monopoly patents bestow, America might have saved three-quarters of its $210 billion bill for prescription drugs. The expense would be worth it if patents brought innovation and prosperity. They don’t.
Innovation fuels the abundance of modern life. From Google’s algorithms to a new treatment for cystic fibrosis, it underpins the knowledge in the “knowledge economy”. The cost of the innovation that never takes place because of the flawed patent system is incalculable. Patent protection is spreading, through deals such as the planned Trans-Pacific Partnership, which promises to cover one-third of world trade. The aim should be to fix the system, not make it more pervasive.
The English patent
One radical answer would be to abolish patents altogether—indeed, in 19th-century Britain, that was this newspaper’s preference. But abolition flies in the face of the intuition that if you create a drug or invent a machine, you have a claim on your work just as you would if you had built a house. Should someone move into your living room uninvited, you would feel justifiably aggrieved. So do those who have their ideas stolen.
Yet no property rights are absolute. When the benefits are large enough, governments routinely override them—by seizing money through taxation, demolishing houses to make way for roads and controlling what you can do with your land. Striking the balance between the claim of the individual and the interests of society is hard. But with ideas, the argument that the government should force the owners of intellectual property to share is especially strong.
One reason is that sharing ideas will not cause as much harm to the property owner as sharing physical property does. Two farmers cannot harvest the same crops, but an imitator can reproduce an idea without depriving its owner of the original. The other reason is that sharing brings huge benefits to society. These spring partly from the wider use of the idea itself. If only a few can afford a treatment, the diseased will suffer, despite the trivially small cost of actually manufacturing the pills to cure them. Sharing also leads to extra innovation. Ideas overlap. Inventions depend on earlier creative advances. There would be no jazz without blues; no iPhone without touchscreens. The signs are that innovation today is less about entirely novel breakthroughs, and more about the clever combination and extension of existing ideas.
Governments have long recognised that these arguments justify limits on patents. Still, despite repeated attempts to reform it, the system fails. Can it be made to work better?
Light-bulb moment
Reformers should be guided by an awareness of their own limitations. Because ideas are intangible and innovation is complex, Solomon himself would find it hard to adjudicate between competing claims. Under-resourced patent-officers will always struggle against well-heeled patent-lawyers. Over the years, the regime is likely to fall victim to lobbying and special pleading. Hence a clear, rough-and-ready patent system is better than an elegant but complex one. In government as in invention, simplicity is a strength.
One aim should be to rout the trolls and the blockers. Studies have found that 40-90% of patents are never exploited or licensed out by their owners. Patents should come with a blunt “use it or lose it” rule, so that they expire if the invention is not brought to market. Patents should also be easier to challenge without the expense of a full-blown court case. The burden of proof for overturning a patent in court should be lowered.
Patents should reward those who work hard on big, fresh ideas, rather than those who file the paperwork on a tiddler. The requirement for ideas to be “non-obvious” must be strengthened. Apple should not be granted patents on rectangular tablets with rounded corners; Twitter does not deserve a patent on its pull-to-refresh feed.
Patents also last too long. Protection for 20 years might make sense in the pharmaceutical industry, because to test a drug and bring it to market can take more than a decade. But in industries like information technology, the time from brain wave to production line, or line of code, is much shorter. When patents lag behind the pace of innovation, firms end up with monopolies on the building-blocks of an industry. Google, for instance, has a patent from 1998 on ranking websites in search results by the number of other sites linking to them. Here some additional complexity is inevitable: in fast-moving industries, governments should gradually reduce the length of patents. Even pharmaceutical firms could live with shorter patents if the regulatory regime allowed them to bring treatments to market sooner and for less upfront cost.
Today’s patent regime operates in the name of progress. Instead, it sets innovation back. Time to fix it.


I would like to honor my Russian's visiters ... Russia is One of World Leaders in Innovation, Scientific Reaserch

Three Russian companies, two universities and the country’s main network of scientific research institutes were listed on a report titled “The Future Is Open: 2015 State of Innovation” published by Thomson Reuters on May 26.

The Intellectual Property (IP) & Science Business of Thomson Reuters is the leading provider of intelligent information of innovative businesses, companies and research institutes.
In the 2014 report, the People's Friendship University was the only Russian entity briefly mentioned in the Thomson Reuters document, after taking a spot in the top 10 Pharmaceuticals, Medical Devices and Food, Tobacco and Beverage sections. Since then, Russia has made a big leap in terms of innovation and scientific research — three Russian companies and three research institutions became the world's leading innovators in five different categories.
Today, Russia is no outsider in the world of innovation, especially when it comes to the categories of Aerospace & Defense and Oil & Gas. Furthermore, Russian scientists are leaders in doing research related to semiconductors and pharmaceuticals, as well as innovations in the field of food, tobacco and beverage.
S. P. Korolev Rocket and Space Corporation Energia, also known as RKK "Energiya," a leading Russian manufacturer of spacecraft and space station components, and JSC Information Satellite Systems — Reshetnev Company, a top Russian satellite manufacturing company, placed fifth and sixth in the list of top space technology innovators with 103 and 52 inventions, respectively, over the period between 2010 — 2014.
Airbus (211), Boeing (210) and Korea Aerospace Research Institute (147) were the world's leading companies in Aerospace & Defense innovations. US-based aerospace and defense production behemoths, Lockheed Martin and NASA, rounded up the list of top space technology innovators with 41 and 28 innovations, respectively.
Fossil fuels remain the backbone of economy. Despite the dramatic plunge in global oil prices over the past year, the level of innovation in the petroleum industry stayed consistent over the last two years. The world's leading oil and gas companies are working hard to come up with cutting-edge technologies that would help them to produce more fuel for the ever-increasing global demand for oil and gas.
Tatneft, an oil and gas company based out of Russia's Republic of Tatarstan, became the leading petroleum and gas exploration innovator in Europe, ahead of Shell Oil, IFP Energy Nouvelles and Saudi Aramco.


Read more: http://sputniknews.com/science/20150527/1022621038.html#ixzz3r6adXan0



Thank you to visit my blog.
If you want to talk to me, add me in my Profile on facebook:

https://www.facebook.com/mayara.rezende.9

or send me an email:

rezendema@hotmail.com

segunda-feira, 19 de outubro de 2015

Brazil's Top 10 Most Innovative Companies

Believe or not in the new corporate mantra: Innovate or Die, here is a list of companies promising rapid growth that you must have on your radar. The top 10 most Innovative Companies in Brazil:
  1. Bug Agentes Biologicos
    Brazil's Top 10 Most Innovative Companies - @Fastcompany
    Brazil's Top 10 Most Innovative Companies - @Fastcompany

  2. Boo-box
  3. Grupo EBX
  4. Stefanini
  5. Embraer
  6. Petrobras
  7. Predicta
  8. F*Hits
  9. Apontador
  10. Vostu
The list was compiled by Fast Company magazine. Launched in 1995 by two former Harvard Business Review editors, Fast Company is one of the main reference in the business of innovation, with over 434 thousand followers on twitter ( @fastcompany ).
Only Bug Agentes Biologicos and Boo-box, the top two Brazilian most innovative companies, made to the Top 50 Most Innovative Companies worldwide. Both expect significant growth in the very near future:
Boo-Box, advertising system for social media, is the 45th most innovative company worldwide: with 31 thousand publishers and 280 thousand websites , it shows 3 billion ads every month to 65 million people and expects to grow exponentially by having a stronger presence in Latin America.
Bug Agentes Biologicos, ranking 33rd worldwide, is a  supplier of predatory insect eggs and parasitoids used for natural protection of crops. It presents a natural alternative to harmful agricultural pesticides and aims Brazil’s $7 billion pesticide market:
Bug’s timing feels right. Brazil is the world’s third-largest agricultural exporter (behind the United States and EU); it recently passed the U.S. as the largest consumer of pesticides. Yet the country has begun to phase out the more noxious chemical pesticides Brazilian farmers use despite diminishing effectiveness. Bug has the only alternative approved by Brazilian agricultural, health, and environmental ministries. It’s currently at 100% capacity with plans in 2012 to double the acreage it covers.
Other than these polemic lists, one of my favorite Fast Company ventures is the 30secondmba website. Although the name is self-explanatory, here is a sample of 30secondMBA : “ Mark Zuckerberg answers How do you generate innovation?”
Besides introducing 30secondsMBA , Zuckerberg’s speech reinforces the idea that innovating does not necessarily include doing something really new; that would be invention. Many entrepreneurs wanna-be focus on inventing instead of innovating. They want to create something really new to launch their startups. Well, it is not really necessary to do so! To prove my point let’s take a look at the top 10 Brazilian startups:
  1. Peixe Urbano (collective shopping site)
  2. LikeStore (enabling purchases via Facebook)
  3. SambaTech (online video)
  4. BuscaPe (price comparison and owner of a chain of ecommerce websites)
  5. Baby (children’s items ecommerce)
  6. OQVestir (ecommerce- women’s clothing)
  7. Clickon (collective shopping site)
  8. Shoes4You (shoes rental)
  9. ViajeNet (tool for booking travels online)
  10. Vostu (games on social networks)
The list was compiled by American Business insider, one of the best 25 Best Financial Blogs in 2011 according to Time.
Brazil’s hottest startup, Peixe Urbano, which means “Urban Fish” in Portuguese, is innovative but not inventive.  Described by Techcrunch as Groupon Clone, Peixe Urbano was one of the first collective shopping site in Brazil. The three Brazilian  co-founders, including Julio Vasconcellos, a graduate of the University of Pennsylvania and Stanford Business School, admit they were inspired by Groupon.
Today, Peixe Urbano is so successful that it won one of Silicon Valley’s most prestigious prizes early this year, the Best International Startup Crunchies award.
My point is: entrepreneurs wanna-be, keep on mind the difference between innovating and inventing. Creating something new is not always necessary when launching a startup.  Improving a process or refining the original concept instead of focusing in the next BIG idea may be the surest way to succeed.
In case one argues that innovating is not as appreciated as inventing, let’s remember that the prize of the Best International Startup was given by Techcrunch, the same entity that described Peixe Urbano a Groupon Clone.



http://www.forbes.com/sites/ricardogeromel/2012/02/21/brazils-top-10-most-innovative-companies/

Nobel Prize in Physics awarded to Arthur B. McDonald

OTTAWA, ONTARIO — The Canada Foundation for Innovation (CFI) congratulates Arthur B. McDonald, a particle physicist and professor emeritus at Queen’s University in Kingston, Ont., who has been named the co-winner of the 2015 Nobel Prize in Physics. The award, announced by the Royal Swedish Academy of Sciences today, will be shared by Japan’s Takaaki Kajita, a physicist at the University of Tokyo.
The Academy recognized the researchers for their discovery of the nature of neutrinos, some of the smallest and most abundant particles of matter in the universe. For years, these subatomic particles were considered to have no mass, a notion that supported the standard model of particle physics. However, in separate observations made in 1998 and 2001, Kajita and McDonald noticed neutrinos changed in ways that required them to have mass, even if this mass was remarkably small.
McDonald made his observations at the Sudbury Neutrino Observatory (SNO), now commonly known as SNOLAB. The particle physics facility is located two kilometres below the Earth’s surface in a nickel mine in Sudbury, Ont. It is the second deepest underground facility in the world. Since 2002, the SNOLAB has received funding through the CFI, most recently through the 2015 Innovation Fund.
McDonald’s discovery, combined with the similar conclusions made by Kajita in Japan’s Super-Kamiokande detector, have inspired particle physicists around the world to investigate the properties of neutrinos, along with other subatomic particles. Their observations have dramatically altered our understanding of the origin and behaviour of matter in the universe.


http://www.innovation.ca/en/AboutUs/News/NobelPrizeinPhysicsawardedArthurBMcDonald